A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease

摘要: Objective: To compare the long-term efficacy and safety of ropinirole with bromocriptine over 3 years in patients early PD limited or no previous dopaminergic therapy. Methods: In this prospective, double-blind, parallel-group study, 335 were randomized to 0.75 mg 1.25 titrated upward at weekly intervals—maximum permitted daily doses 24 ropinirole, 40 bromocriptine. Results: Approximately one third each group withdrew prematurely, mostly because adverse experiences; 61/102 (60%) ropinirole-treated 59/112 (53%) bromocriptine-treated completed study on dopamine agonist alone. Mean for all completion 12 (SD 6) 8) Occurrence experiences both groups was similar. Emergence dyskinesias low. Both treatments induced marked improvements Unified Parkinson’s Disease Rating Scale activities living (ADL, Part II) motor (Part III) scores first weeks, which maintained during study. After years, had a mean improvement score 31% compared 22% (p = 0.086) significantly better ADL (treatment difference 1.46 points, p 0.029). Conclusions: agonists are effective treatment high proportion patients; effectiveness persists least years. Those who functional status than